Biosimilar Testing and Development Services: A Market Poised for Exponential Growth
The biosimilar testing and development services market is experiencing rapid growth, projected to surge from $2.5 billion in 2022 to $7.8 billion by 2032, reflecting a robust CAGR of 12.1%. This expansion is driven by the increasing demand for cost-effective biosimilars, the rising prevalence of chronic diseases, and the expiration of patents for key biologic drugs. As the healthcare landscape evolves, biosimilar testing and development services are becoming essential for ensuring safety, efficacy, and regulatory compliance.
Comments
Post a Comment